Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.

Autor:	Stellato, Daniel1 (AUTHOR), Thabane, Marroon E.2 (AUTHOR), Chandiwana, David2 (AUTHOR), Park, Jinhee2 (AUTHOR), Delea, Thomas E.1 (AUTHOR) tdelea@pai2.com
Zdroj:	PharmacoEconomics. Jul2021, Vol. 39 Issue 7, p853-867. 15p.
Databáze:	Business Source Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink